Key Highlights
- GMAB shares rose approximately 3% in pre-market trading to $28.74, up from a prior close of $28.01.
- The European Commission approved TEPKINLY plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
- The combination is the first bispecific-based therapy approved in Europe for follicular lymphoma in the second-line setting.
- The Phase 3 EPCORE FL-1 trial showed a 79% reduction in the risk of disease progression or death versus standard care.
European Commission Grants Follicular Lymphoma Approval
Genmab A/S (NASDAQ:GMAB) shares moved higher in pre-market trading after the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. Genmab is a Copenhagen, Denmark-based biotechnology company focused on developing antibody therapeutics for cancer and other serious diseases, and it markets TEPKINLY alongside partner AbbVie.
The approval is based on results from the Phase 3 EPCORE FL-1 trial, which compared fixed-duration TEPKINLY plus the combination regimen against standard-of-care treatment alone. The trial demonstrated a statistically significant improvement in progression-free survival and overall response rates, with the combination reducing the risk of disease progression or death by 79% and approximately three out of four patients achieving a complete response. The approved combination represents the first bispecific-based therapy cleared in Europe for follicular lymphoma in the second-line setting, offering a chemotherapy-free treatment option.
Financial Position and Commercial Portfolio
Genmab carries a market capitalization of approximately $17.2 billion following the pre-market move, with a price-to-earnings ratio of roughly 20 and earnings per share of $1.39. Shares have traded within a 52-week range of $20.33 to $35.43. The company's commercial portfolio includes eight approved products developed using its proprietary antibody technology platforms, with DARZALEX standing as its leading commercial asset through a partnership arrangement.
TEPKINLY was already approved in Europe for certain lymphoma indications prior to this expanded authorization, and the new approval broadens its addressable patient population to include second-line follicular lymphoma patients seeking chemotherapy-free options.
Conclusion
The expanded European approval adds a new indication to an already-approved therapy, reinforcing TEPKINLY's position across multiple lymphoma subtypes without requiring a new regulatory pathway from scratch. Investors will likely watch adoption trends in the newly approved second-line setting alongside any further label expansions for the bispecific antibody platform.
FAQs
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...